First siRNA drug trail approved by DCGI in India
Biocon and Quark Pharmaceuticals announced the randomization of the first patient in India in the pivotal global phase II/ III study of QPI-1007, a novel siRNA (small interfering RNA) drug candidate for ocular neuroprotection.Biocon and its partner, Quark Pharmaceuticals, have received approval from the Drug Controller General of India to proceed with the study, the first ever clinical trial of a siRNA therapy in India.
Biocon and Quark Pharma had entered into a licensing and collaboration agreement in 2013 to co-develop, manufacture and commercialise QPI-1007 in India and other key markets.
Powered by Capital Market - Live News
